guest ::
| Home > Publications database > New treatment strategies for primary lymphoma of the central nervous system.[Neue Therapiestrategien beim primären Lymphom des Zentralnervensystems]. |
| Home > Publications database > New treatment strategies for primary lymphoma of the central nervous system.[Neue Therapiestrategien beim primären Lymphom des Zentralnervensystems]. |
| Journal Article (Review Article) | DKFZ-2023-02244 |
; ;
2024
Springer
Heidelberg
This record in other databases: 
Please use a persistent id in citations: doi:10.1007/s00115-023-01561-w
Abstract: Primary central nervous system lymphomas (PCNSL) are rare highly aggressive diffuse large B cell non-Hodgkin lymphomas confined to the brain, meninges, the spinal cord and the eyes. Although the implementation of high-dose methotrexate-based chemotherapy has significantly improved the prognosis of PCNSL during the last decades, about one third of patients show refractory disease and about half of the patients eventually relapse after having achieved complete response. This highlights the need for novel treatment strategies. The most promising progress has been made in the field of molecular targeted therapy that interferes with the oncogenic signaling pathways of PCNSL. These include inhibitors of Bruton tyrosine kinase and inhibitors of the PI3K/mTOR signaling pathway. In addition, the thalidomide analogues lenalidomide and pomalidomide, which belong to the class of immunomodulators, show efficacy in the treatment of PCNSL. As immune evasion appears to play a relevant pathogenetic role in PCNSL, immunotherapies in the treatment of PCNSL are the subject of intensive research. Promising initial clinical data are available for both immune checkpoint inhibitors and cellular immunotherapy with chimeric antigen receptor (CAR) T cells. Before the widespread clinical application of these novel therapies, the efficacy needs to be confirmed in larger prospective studies. Despite high response rates, targeted therapies and immunotherapy often fail to achieve lasting tumor control. Therefore, novel approaches are currently being investigated in combination protocols.
Keyword(s): B cell non-Hodgkin lymphoma ; B cell receptor pathway ; Chimeric antigen receptor T cells ; Immunotherapy ; Molecular targeted therapies
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Springer ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
